NYSE · ENOVHealthcareOrthopedic & Surgical Supplies

Enovis financials

$18.27−1.03%
Close Sep 30, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
Revenue$2.25B$2.11B$1.71B$1.56B
Gross profit$1.35B$1.18B$990.8M$869.4M
Gross margin59.8%56.0%58.0%55.6%
Operating income-$1.12B-$775.7M-$65.7M-$71.2M
Net income-$1.18B-$825.5M-$33.3M-$13.3M
Net margin−52.7%−39.2%−1.9%−0.9%
Diluted EPS$-20.75$-14.93$-0.61$-0.25
EBITDA$229.7M$181.4M$168.7M$129.1M
Operating cash flow$217.3M$113.5M$135.0M-$55.9M
Free cash flow$19.9M-$67.2M$12.8M-$161.3M
Diluted shares57.1M55.3M54.5M54.1M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31
Cash & equivalents$36.4M$48.2M$36.2M$24.3M
Short-term investments$0.00$0.00$0.00$0.00
Total debt$1.30B$1.33B$466.2M$259.3M
Total assets$3.83B$4.72B$4.51B$4.27B
Total liabilities$2.34B$2.15B$1.09B$823.4M
Shareholders' equity$1.49B$2.56B$3.42B$3.45B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology